ArticlePloS one2025
Burdens of Gastroesophageal Reflux Disease in China: Findings from the 2021 GBD Study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a major global health concern, Gastroesophageal Reflux Disease (GERD) has garnered widespread attention; However, to date, the prevalence of GERD across different ethnic groups in China has not been comprehensively examined by any large-scale epidemiological studies or meta-analyses. Against this backdrop, the present study draws on data from the Global Burden of Disease (GBD) Study to investigate the burden of GERD in China. Data from the 2021 GBD Study were utilized to assess the burden of GERD in China, focusing on key indicators such as prevalence, incidence, Years of Life Lived with Disability (YLDs), Age-Standardized Rates (ASR). Health inequality analyses were used to measure the inequality in the distribution of GERD across countries based on the Socio-Demographic Index (SDI), as well as to determine whether such inequality exists in China. Frontier analysis identified top performers in healthcare systems across different countries when examining the burden of GERD, followed by a comparison of differences in GERD burden between China and these top-performing countries. The trends of GERD from 2022 to 2044 were projected using the Nordpred and ARIMA model. Between 1990 and 2021, the prevalence of GERD in China experienced a notable rise of 60.62%. Correspondingly, the ASR also increased significantly. A similar pattern was Observed in incidence and YLDs, with number and ASR rising. A frontier analysis revealed that China had relatively low prevalence and incidence rates but a moderate-to-high level of SDI. Health inequality analysis revealed both absolute and relative inequalities related to SDI, with a noticeable increase in the inequality of the age-standardized GERD burden from 1990 to 2021. a significantly greater inequality in GERD burden was observed in China compared to other countries, suggesting a disparity in GERD distribution relative to SDI. Projections of GERD in China extending from 1990 to 2044 indicate a steady increase in the combined numbers and ASR of prevalence, incidence, and YLDs. The disease burden of GERD in China has risen steadily over the past three decades, with marked increases in the ASRs of its prevalence, incidence, and YLDs. Given the growing number of individuals affected by GERD, adapting healthcare systems to address the escalating demand for related services and treatments has become an urgent necessity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.